• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Pharmasset Launches Pivotal Phase III of PSI-7977 in HCV

Nov. 2, 2011
By Marie Powers
The next generation of hepatitis C virus (HCV) therapies moved a step closer to the corner drugstore with the initiation of Pharmasset Inc.'s pivotal Phase III studies of the HCV nucleotide analogue PSI-7977. The program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in three groups of patients with HCV, independent of viral genotype or their ability to take interferon therapy.The Princeton, N.J.-based company expects to submit data from the three Phase III trials in the second half of 2013, both in the U.S.
Read More

AgonOx, MedImmune Partner on T-Cell Modulator Program

Nov. 1, 2011
By Marie Powers
Privately held AgonOx LLC, which could afford to be picky with its hot T-cell technology, selected MedImmune LLC, a unit of AstraZeneca plc, over more than two dozen other potential suitors for an exclusive global agreement to develop agonists and other immune system activators for cancer therapy using AgonOx's OX40 platform.OX40 is a protein transiently expressed on the surface of effector T-cells, but only after activating the T-cells with immune-stimulating antigens, including tumor antigens.
Read More

Salix Stock Slammed on Word of CRL for Xifaxan

Oct. 31, 2011
By Marie Powers
Salix Pharmaceuticals Ltd. delivered bad news to investors Thursday morning. Based on a phone call with the FDA Wednesday evening, the Raleigh, N.C.-based company now expects to receive a complete response letter (CRL) on its supplemental new drug application (sNDA) for Xifaxan (rifaximin) 550-mg tablets for the treatment of non-constipation irritable bowel syndrome (non-CIBS) and IBS-related bloating.
Read More

Portola Lands Syk Inhibitor Deal with Biogen Idec

Oct. 28, 2011
By Marie Powers
Fresh off a big score at the Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis conference in Amsterdam, the Netherlands, for its oral multiple sclerosis immune modulator BG-12, Biogen Idec has inked a multi-million-dollar deal with privately held Portola Pharmaceuticals Inc. (See BioWorld Today, Oct.
Read More

Onyx, Bayer Enjoy 'Upside Surprise' on Regorafenib

Oct. 27, 2011
By Marie Powers
Ahead of schedule, on Wednesday Onyx Pharmaceuticals Inc. and partner Bayer HealthCare Pharmaceuticals reported positive Phase III data for the VEGF-multikinase inhibitor regorafenib (BAY 73-4506) in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard treatment.While keeping details under wraps, the companies said the trial met its primary endpoint of statistically significant improvement in overall survival.
Read More

Gilead Sciences, GlobeImmune Cook Up HBV Vaccine Deal

Oct. 26, 2011
By Marie Powers
Gilead Sciences Inc. and privately held GlobeImmune Inc. turned up the heat on an already sizzling hepatitis space by inking an exclusive worldwide license and collaboration to develop therapeutic vaccines that use Gilead's Viread (tenofovir disoproxil fumarate) and other oral therapies to treat chronic hepatitis B virus (HBV).
Read More

Cubist to Buy Adolor in Potential $415M Deal

Oct. 25, 2011
By Marie Powers
Cubist Pharmaceuticals Inc., which focuses on the development of drugs to combat conditions prevalent in the hospital setting, will expand its product pipeline with the acquisition of Adolor Corp. in a deal potentially valued at $415 million.
Read More

Sunshine Biopharma Targets Multidrug-Resistant Cancer

Oct. 21, 2011
By Marie Powers
Canadian biotech Sunshine Biopharma Inc. is seeking to bring a ray of light to women with multidrug-resistant breast cancer by arresting the rapid development and spread of their disease.
Read More

Start-up Arteaus Raises $18M To Test CGRP Drug in Migraine

Oct. 20, 2011
By Marie Powers
Biotech start-up Arteaus Therapeutics LLC raised $18 million in a Series A financing from Atlas Venture, of Cambridge, Mass., and OrbiMed Advisors, of New York, to advance a migraine headache antibody technology licensed from Eli Lilly and Co.
Read More

NewCo News: Stealth Moves Mitochondrial Candidate into Phase II Trials

Oct. 7, 2011
By Marie Powers
Despite its moniker, privately held Stealth Peptides Inc. is poised to make a name for itself in the development of mitochondrial-targeted therapies, potentially addressing cardiovascular, renal, ophthalmologic, neurologic and metabolic indications.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 12, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe